Polaris AI Pharma

041910 · KOSDAQ · Health Care · SMALL CAP

Revenue down 6.8% in FY2025.

Polaris AI Pharma reported separate results for FY2025: revenue of US$37.5M (−6.8% year on year), operating profit of US$2.16M (+1712.2% year on year) and net income of US$4.16M (+56.1% year on year).

Earnings(Change of 30% or more in revenue or profit/loss structure (15% for large companies))· FILED 2026-03-06· RCEPT 20260306901428

US$37.5MRevenue
−6.8%Revenue vs a year earlier
US$2.16MOperating profit

Converted at 1 USD ≈ ₩1,479.51 (filing-date rate, 2026-03-06 close)

What happened

Polaris AI Pharma reported separate results for FY2025: revenue of US$37.5M (−6.8% year on year), operating profit of US$2.16M (+1712.2% year on year) and net income of US$4.16M (+56.1% year on year).

Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.

RevenueUS$37.5M
Revenue vs a year earlier−6.8%
Operating profitUS$2.16M
Net incomeUS$4.16M
PeriodFY2025 (separate)
Filed2026-03-06, Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SourceDART rcept 20260306901428 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-03-06 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.